Mesenchymal Stem Cells for Chronic Kidney Diseases

Inclusion Criteria: * Agreement to participate in the trial and provision of signed written informed consent * Pathological diagnosis of diabetic nephropathy or hypertensive renal damage * 15 ≤ eGFR \< 60 mL/min/1.73m², UACR \> 300 mg/g * Age ≥ 18 years Exclusion Criteria: * Extremely severe anemia (hemoglobin \< 30 g/L) * Received blood product transfusion therapy within 1 month * Autosomal dominant or recessive polycystic kidney disease (ADPKD) * History of kidney transplant or other solid organ transplant * Active systemic or localized infection (e.g., pneumonia, osteomyelitis) * Allergy to stem cells themselves or stem cell-related culture medium * History of allergic reaction to cell products (e.g., blood transfusion, platelets) * History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis) * History of malignancy or current malignant disease * Elevated tumor markers (AFP, CEA, CA199, CA125, etc.) * Pregnant women or women with plans for pregnancy within 3 months after MSC therapy * Participation in drug-related clinical trials within the past 2 months * Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health